Phibro Animal Health Corporation (PAHC)

Animal health pharmaceuticals and nutrition maker. Read November 9, 2026 from the annual report for the period ending June 30, 2026, filed August 26, 2026. Ranked 106 of the 145 Healthcare companies read so far, by the share within reach now.

The filing states approximately 2,605 employees at June 30, 2026 in 37 countries and describes animal health pharmaceutical, vaccine and nutrition plants with no count by segment, so the pharmaceutical manufacturing leads with the nutrition products at animal food manufacturing by description.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 30% now, 37% at the end of 2027, 40% at the end of 2028, 40% at the end of 2030. By the patterns, the work is about 40% desk work, 13% people work and 47% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 61% of the working time stays with people (conversation, in-person and hands-on work), 34% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

2,605 employees as of June 30, 2026 (stated). Not stated; employees are in 75 locations across 37 countries with no count by country.

The filing: “As of June 30, 2026, we had approximately 2,605 employees in 75 locations spanning 37 countries.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 2,605 employees at June 30, 2026 in 75 locations across 37 countries, up from 2,475; certain Brazilian employees under regional industry unions and certain Israeli and U.S. employees under site collective bargaining agreements; the Denison culture survey in 2017, 2023 and 2025; the filing says the Chicago Heights plant is to close with production shutdown expected in summer 2027 and its products relocated.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Johnson & Johnson (JNJ, 140,800 employees)30% now, 41% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)36% now, 53% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)32% now, 44% by 2028
• Pfizer Inc. (PFE, 75,000 employees)32% now, 44% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)32% now, 44% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)32% now, 44% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)32% now, 44% by 2028
• Amgen Inc. (AMGN, 31,500 employees)32% now, 44% by 2028

What the filing says about AI

9 sentences in the filing name AI. The filing says it uses and is expanding the use of machine learning and artificial intelligence in its business, and names the operational, competitive and reputational risks of managing that use improperly.

• “Examples of such risks and uncertainties include: ● outbreaks of animal diseases could significantly reduce demand for our products or availability of raw materials; ● perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products could cause a decline in the sales of those products; ● restrictions on the use of antibacterials in food-...”
• “In addition, we may not have sufficient funds to finance repayment of any of such indebtedness upon any such "change in control." We use machine learning and artificial intelligence (AI) in our business, and challenges with properly managing its use could result in operational, competitive or reputational harm.”
• “We currently use and are expanding the use of machine learning and AI in our business.”
• “Machine learning and AI are new and rapidly evolving technologies, the use of which presents a number of operational, compliance and reputational risks.”
• “AI algorithms are currently known to sometimes produce unexpected results or behave in unpredictable ways that can generate irrelevant, nonsensical, deficient, factually inaccurate or biased content and results.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 20240median 4
• Fiscal 202510median 10
• Fiscal 20269

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The filing counts nothing by segment or plant, so the split between pharmaceutical and nutrition manufacturing is by description (c); the data service's segment table (Vaccines 100%) is not the filing's segments and was not used.
• The U.S. share is not stated.
• The union share is stated in words and left null.

Source: the company's annual report on EDGAR, accession 0001104659-26-101493, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.